Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers

<p>Are you aware that programmed cell death-ligand 1 (PD-L1) testing may not be needed to guide immunotherapy decisions in resectable gastric/gastroesophageal junction (GEJ) cancers?<br />  <br /> Credit available for this activity expires: 9/22/2026<br /> Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/1002919?ecd=bdc_podcast_libsyn_mscpedu" target="_blank" rel= "noopener">https://www.medscape.org/viewarticle/1002919?ecd=bdc_podcast_libsyn_mscpedu</a></p>